Achieve Life Sciences Inc. ACHV, +12.88% announced Tuesday that a second late-stage confirmatory trial of its cytisinicline to quit smoking and nicotine dependency achieved positive results. The study showed a statistically significant advantage compared with placebo. The Phase 3 trial included 792 adult smokers in 20 U.S. trial sites who received 3mg of the cytisinicline three times daily for six or twelve weeks. The primary endpoint of the Phase 3 trial was biochemically confirmed smoking cessation 24 weeks after randomization. The company stated that both the 6-week and 12-week cytisinicline treatments demonstrated statistically significant reductions in smoking compared to the placebo. In the U.S., there are approximately 28,3 million adult smokers. Globally, more than one billion people smoke. Achieve Life Sciences estimates that 8 million people worldwide die from smoking-related diseases every year. The company has begun working with regulators on bringing cytisinicline onto the market. The stock rose 1.6% in premarket trading and has gained 233% year-to-date, while the S&P500 SPX +0.02% is up 9%.